Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
Koda Health and UPMC Enterprises Collaborate to Prove Out the Value of Advance Care Planning (ACP) at Scale
Backed by Strategic Investment from UPMC Enterprises, Koda Health Scales AI-Enhanced Advance Care Planning Across Complex Populations
Koda Health, an AI-enhanced Advance Care Planning (ACP) platform, today announced a strategic investment from UPMC Enterprises as part of the company’s Series A raise.
The investment reflects UPMC Enterprises’ conviction that digitally guided, values-based advance care planning represents a critical and underbuilt layer of serious illness infrastructure.
Koda’s platform guides patients through condition-specific care planning conversations via video and guided education, helping them document their values, care wishes, medical decision-makers, and treatment preferences. High acuity patients are paired with a dedicated Koda Member Advocate — a clinician with a background in palliative nursing or social work — who provides longitudinal support throughout the care planning process. These advocates ensure advance care plans are complete, surrogates are aligned, and that members receive the care that matters most to them during serious illness. Patient preferences flow directly into clinical workflows, ensuring care teams have access to patient goals at the moments that matter most.
An estimated $200 billion is spent each year on care that patients would not have wanted had they been engaged in their care planning earlier. ACP is proven to close that gap, but has historically been difficult to deliver at scale. Koda Health has demonstrated a 79% reduction in terminal hospitalizations, a 38% reduction in ICU utilization, and a 19% reduction in total cost of care for patients in the last year of life in a third-party validated study.
“UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market. It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what’s possible,” said Dr. Desh Mohan, Co-Founder and Chief Medical Officer at Koda Health.
“UPMC Enterprises invests in companies building infrastructure that improves how care is delivered for patients who need it most,” said Kathryn Heffernan, Senior Director at UPMC Enterprises…
Full release here, originally announced April 28th, 2026.
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
- The Financing Combines a $50M Series D Investment by Boehringer Ingelheim with Additional Dedicated Funding to Support Commercialization; As Part of the Agreement, Boehringer is Transferring Responsibility for Commercializing CT-155 to Click Therapeutics
- Granted Breakthrough Device Designation by the FDA in 2024, the CT-155 Phase III CONVOKE Study was the First and Only Pivotal Trial to Show a Statistically Significant Reduction in Experiential Negative Symptoms of Schizophrenia as an Adjunct to Standard of Care Antipsychotic Treatment
- Treatment with CT-155 Demonstrated a Cohen’s D Effect Size of -0.36 (p Value= 0.0003) Reflective of a 6.8-Point Improvement of Negative Symptoms Severity as Measured by CAINS-MAP at 16 Weeks (vs. 4.2-Point in Digital Control Arm), Representing a 62% Relative Improvement
- Click Therapeutics’ Expertise in Digital Therapeutics, Experience in the Mental Health Space, and Commitment to Patient-Centric Approaches Position the Company Well to Bring this Important Therapy to Patients
Boehringer Ingelheim and Click Therapeutics today announced a strategic agreement to support the commercialization of CT-155, an investigational prescription digital therapeutic that is being studied for the treatment of the experiential negative symptoms of schizophrenia in adults aged 18 years and older. Under the agreement, Boehringer will transfer full product responsibility, including all commercial and marketing authorization rights, to Click Therapeutics. To support this transition, Boehringer has made a $50M Series D strategic investment and provided dedicated commercial funding to help bring CT-155 to patients, if cleared by the FDA. CT-155 was co-developed by Boehringer and Click.
“Boehringer Ingelheim’s selection of Click to deliver CT-155 to patients is powerful validation of our vision and the capabilities we have spent over a decade building,” said David Benshoof Klein, CEO and founder of Click Therapeutics. “We are eager to take the lead with CT-155 and are focused on getting this FDA-designated Breakthrough Device to patients after clearance by the FDA.”
At the core of Click’s commercialization strategy will be the clinical data from the Phase III CONVOKE study (CONVOKE; NCT05838625). The randomized, double-blind, controlled study investigated the effectiveness and safety of CT-155 versus a digital control app as an adjunct to standard of care antipsychotic therapy in people diagnosed and living with schizophrenia experiencing negative symptoms.
The study met its primary endpoint, as presented at the 38th Annual European College of Neuropsychopharmacology (ECNP) Congress, which was change in experiential negative symptoms from baseline to 16 weeks as measured by the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP). Treatment with CT-155 demonstrated a Cohen’s D effect size of -0.36 (p value= 0.0003) reflective of a 6.8-point improvement of negative symptoms severity as measured by CAINS-MAP at 16 weeks (vs. 4.2-point in digital control arm), representing a 62% relative improvement.
CT-155 was well-tolerated and demonstrated an adverse event (AE) profile consistent with past studies. The AE rates with CT-155 and the digital control arm were 8.3% vs 13.4%, respectively. There were no trial discontinuations attributed to CT-155 and two (2) for the digital control arm. There were no serious AEs related to either group…
Full release here, originally announced April 9th, 2026.
No comments:
Post a Comment